Level 2 · Controlled trialRandomised controlled trial

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial

Ma LX, Titmuss E, Loree JM, Jonker DJ, Kennecke HF, Berry S, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski S, Tu D, O'Callaghan C, Chen EX

Journal for immunotherapy of cancer · 4 December 2024

AUTHORS’ ABSTRACT

The abstract of this article is not reproduced here: its licence does not allow it. It can be read freely on the journal’s website or on Europe PMC.

Scientific information content; it does not replace the advice of a healthcare professional. The presence of a study in this library does not constitute a claim about our products.

← All studies
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial | Ingredient Superfood